Positively Aware Evotaz

Evotaz

atazanavir/cobicistat (ATV/COBI)

Recommended as component of initial regimen in certain clinical situations
Protease Inhibitor

Standard Dose

One tablet once daily with food. Each tablet contains 300 mg of atazanavir boosted by 150 mg cobicistat. Must be taken in combination with another antiretroviral(s) which does not contain the medications in this drug or medication from the same drug classes. Use with Intelence or Sustiva is not recommended.



Use in treatment-experienced patients depends on protease inhibitor drug resistance. Co-administration with drugs containing tenofovir disoproxil fumarate (Viread, found in Atripla, Cimduo, Complera, Delstrigo, Stribild, Symfi, Symfi Lo, and Truvada) is not recommended if kidney function as measured by creatinine clearance is below 70 mL/min. Co-administration with drugs containing tenofovir alafenamide (Vemlidy, found in Biktarvy, Descovy, Genvoya, Odefsey, and Symtuza) is not recommended if kidney function as measured by creatinine clearance is below 30 mL/min.



Not recommended in people with any degree of liver impairment or those who are treatment-experienced and on hemodialysis.



Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Evotaz is not recommended during pregnancy due to substantially lower exposures of atazanavir and cobicistat during pregnancy. Cobicistat has not been studied separately from Genvoya and Stribild in individuals under 18 years of age; thus, Evotaz should not be used in pediatric patients.

Manufacturer

Bristol-Myers Squibb
evotaz.com
(800) 321-1335

AWP

$1,926.56/month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments